Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, ...

Duvakitug, a drug candidate with a "best in class efficacy profile," has shown strong remission rates in treatment-refractory patients. Analysts are particularly optimistic about its consistent ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV’574/SAR447189) for moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of ...

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ETNew detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across ...

The company's pipeline is equally promising, with several potential blockbusters in development. Duvakitug, a drug candidate with a "best in class efficacy profile," has shown strong remission rates ...